Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Notes Payables (2016 - 2024)

Corbus Pharmaceuticals Holdings has reported Notes Payables over the past 10 years, most recently at $301000.0 for Q4 2023.

  • For Q4 2023, Notes Payables fell 14.81% year-over-year to $301000.0; the TTM value through Dec 2023 reached $301000.0, down 14.81%, while the annual FY2023 figure was $301000.0, 14.81% down from the prior year.
  • Notes Payables for Q4 2023 was $301000.0 at Corbus Pharmaceuticals Holdings, up from $51157.0 in the prior quarter.
  • Over five years, Notes Payables peaked at $767938.0 in Q4 2021 and troughed at $51157.0 in Q2 2023.
  • A 5-year average of $339369.5 and a median of $301000.0 in 2023 define the central range for Notes Payables.
  • Biggest five-year swings in Notes Payables: soared 90.88% in 2019 and later crashed 53.99% in 2022.
  • Year by year, Notes Payables stood at $752659.0 in 2019, then dropped by 5.65% to $710158.0 in 2020, then rose by 8.14% to $767938.0 in 2021, then crashed by 53.99% to $353323.0 in 2022, then decreased by 14.81% to $301000.0 in 2023.
  • Business Quant data shows Notes Payables for CRBP at $301000.0 in Q4 2023, $51157.0 in Q2 2023, and $203258.0 in Q1 2023.